Ownership Action Don’t Lie: Atossa Genetics Inc (NASDAQ:ATOS): Institutional Investors Are Worried

November 21, 2016 - By Darrin Black   ·   0 Comments

Ownership Action Don't Lie: Atossa Genetics Inc (NASDAQ:ATOS): Institutional Investors Are Worried

Sentiment for Atossa Genetics Inc (NASDAQ:ATOS)

Atossa Genetics Inc (NASDAQ:ATOS) institutional sentiment decreased to 0 in Q2 2016. Its down -1.00, from 1 in 2016Q1. The ratio dropped, as 6 hedge funds increased and started new equity positions, while 6 cut down and sold positions in Atossa Genetics Inc. The hedge funds in our partner’s database now own: 1.41 million shares, up from 1.36 million shares in 2016Q1. Also, the number of hedge funds holding Atossa Genetics Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 2 Increased: 2 New Position: 4.

Atossa Genetics Inc. is a clinical-stage pharmaceutical firm focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company has a market cap of $6.78 million. The Company’s leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts. It currently has negative earnings. It has initiated a Phase II clinical study using its microcatheters to deliver fulvestrant as a treatment of ductal carcinoma in-situ and breast cancer.

The stock closed at $1.78 during the last session. It is down 59.08% since April 19, 2016 and is downtrending. It has underperformed by 62.94% the S&P500.

According to Zacks Investment Research, “Atossa Genetics Inc. is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. The Company’s diagnostic tests consist of medical devices which can collect fluid samples from the breast milk ducts. It is also conducting research on the treatment of pre-cancerous cells by using its FDA-cleared microcatheters to deliver, directly into the milk ducts, anti-cancer drugs that can be used to treat the pre-cancerous lesions. Atossa Genetics Inc. is headquartered in Seattle, WA.”

Bank Of America Corp De holds 0% of its portfolio in Atossa Genetics Inc for 346 shares. Blackrock Fund Advisors owns 8,726 shares or 0% of their US portfolio. Moreover, Blackrock Institutional Trust Company N.A. has 0% invested in the company for 111,034 shares. The Massachusetts-based Commonwealth Equity Services Inc has invested 0% in the stock. Geode Capital Management Llc, a Massachusetts-based fund reported 86,072 shares.#img1#

ATOS Company Profile

Atossa Genetics Inc., incorporated on April 30, 2009, is a clinical-stage pharmaceutical firm focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company’s leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts. It has initiated a Phase II clinical study using its microcatheters to deliver fulvestrant as a treatment of ductal carcinoma in-situ (DCIS) and breast cancer. The Company’s second pharmaceutical program under development is Afimoxifene Topical Gel (AfTG) for the treatment and prevention of hyperplasia of the breast. It is also engaged in the process of evaluating other therapeutic candidates to treat other breast conditions, including breast cancer. The Company’s medical devices include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator. These devices are intended for the collection of nipple aspirate fluid (NAF) for cytological testing at a laboratory. It holds the worldwide exclusive rights to develop and commercialize AfTG for the treatment and prevention of hyperplasia of the breast. The active pharmaceutical ingredient in AfTG is Afimoxifene (4-hydroxytamoxifen), which is an active metabolite of tamoxifen. Afimoxifene is an anti-estrogen with an affinity for estrogen receptor that is up to approximately 50 fold higher compared with that of tamoxifen. AfTG is a transdermal gel formulation of Afimoxifene. It is evaluating AfTG for use in several patient populations, including high risk women as determined by family history; women with breast hyperplasia, and women with a biopsy showing either atypical hyperplasia or DCIS. AfTG can be dispensed from a metered-dose container. A total of over 16 Phase I and Phase II studies have been conducted in various indications in the United States, United Kingdom, France, Poland and Czech Republic.

More news for Atossa Genetics Inc (NASDAQ:ATOS) were recently published by: Quotes.Wsj.com, which released: “News Atossa Genetics Inc.ATOS” on October 02, 2012. Seekingalpha.com‘s article titled: “Ambitious Atossa Genetics Going After Two Breast Cancer Blockbusters” and published on December 10, 2015 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Darrin Black


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>